Infliximab in Polymyositis/Dermatomyositis/Inclusion Body Myositis
Principal Investigator:
Ingrid Lundberg, Karolinska Institute
Study Design:
Phase 2 Open trial, Infliximab dose 5 mg/kg
Types & Number of IIM Studied:
Active Polymyositis/Dermatomyositis/Inclusion Body Myositis with reduced
muscle function (N = 15)
Entry Criteria:
Refractory to prednisolone and methotrexate
IMACS Core Set Measures Included:
Physician and Patient Global Activity and Damage Assessments, Health
Assessment Questionnaire, Manual Muscle Testing, muscle enzymes, Myositis
Disease Activity Assessment Tool; Myositis Damage Index, Health-Related
Quality of Life by SF-36
|